Effect of two common GVHD prophylaxis regimens on the gut microbiome in a randomized phase 3 trial

Jakob Wirbel, Wael Saber, Michael J. Martens, Jonathan U. Peled, Tessa M. Andermann, Teng Fei, Erin F. Brooks, Boryana Doyle, Nathan B. Pincus, Robert R. Jenq, Merav Bar, Javier Bolaños-Meade, Brandi Bratrude, Saurabh Chhabra, Sung Won Choi, William Clark, Suman R. Das, Hany Elmariah, Mahasweta Gooptu, Shernan G. Holtan, Richard J. Jones, John E. Levine, Brent R. Logan, Monzr M. Al Malki, Hemant S. Murthy, Armin Rashidi, Andrew R. Rezvani, Marcie L. Riches, Lyndsey Runaas, Karamjeet Sandhu, Ashl
Nature Medicine · Springer Nature · 2026-11-12 · DOI: 10.1038/s41591-026-04712-z

Аннотация

Nature Medicine, Published online: 12 November 2026; doi:10.1038/s41591-026-04712-z In a prespecified companion study (BMT CTN 1801) of the randomized phase 3 BMT CTN 1703 trial comparing two common GVHD prophylaxis regimens, microbiome diversity at engraftment did not associate with non-relapse mortality, but secondary analyses found baseline microbiome diversity was associated with clinical outcomes.

Читать у издателя →

Похожие статьи